Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial
Xuanyi Wang, Syed Faisal Mahmood, Fang Jin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1910-1919
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 77
RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2
Rang Feng, Ruo‐Yi Xue, Chang Liu, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 28
Broad-spectrum pan-genus and pan-family virus vaccines
Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 6, pp. 902-916
Open Access | Times Cited: 24
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 9
Modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China
Kathy Leung, GM Leung, Joseph T. Wu
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 31
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
Zhiren Zhang, Qiaren He, Wei Zhao, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 14, pp. 4164-4164
Open Access | Times Cited: 23
CHO cells for virus-like particle and subunit vaccine manufacturing
Zalma V. Sanchez-Martinez, Sergio P. Alpuche-Lazcano, Matthew Stuible, et al.
Vaccine (2024) Vol. 42, Iss. 10, pp. 2530-2542
Open Access | Times Cited: 6
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine
Georgia Deliyannis, Nicholas A. Gherardin, Chinn Yi Wong, et al.
EBioMedicine (2023) Vol. 92, pp. 104574-104574
Open Access | Times Cited: 13
A Review of Protein-Based COVID-19 Vaccines: From Monovalent to Multivalent Formulations
Qian Gui, Cuige Gao, Miaomiao Zhang, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 579-579
Open Access | Times Cited: 5
Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster
Terry Nolan, Georgia Deliyannis, Maryanne Griffith, et al.
EBioMedicine (2023) Vol. 98, pp. 104878-104878
Open Access | Times Cited: 11
COVID-19 vaccines: A comprehensive review of safety and efficacy
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Elsevier eBooks (2025), pp. 685-777
Closed Access
Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2
Yifan Lin, Xuejiao Liao, Xuezhi Cao, et al.
Journal of Clinical Investigation (2025)
Open Access
Immunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A)
K. S. Korsak, Е. В. Воропаев, О. В. Осипкина, et al.
Health and Ecology Issues (2025) Vol. 21, Iss. 4, pp. 26-36
Closed Access
A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a
Zi‐Wei Ye, Chon Phin Ong, Hehe Cao, et al.
EBioMedicine (2025) Vol. 114, pp. 105662-105662
Closed Access
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
Abisha Shyji. P. S, Apoorva Wasnik, Latika Gupta, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Angelina Kovalenko, Ekaterina M. Ryabchevskaya, Ekaterina A. Evtushenko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1701-1701
Open Access | Times Cited: 9
Mucosal vaccine development for respiratory viral infections
Yifan Lin, Zhenxiang Hu, Yang‐Xin Fu, et al.
hLife (2023) Vol. 2, Iss. 2, pp. 50-63
Open Access | Times Cited: 9
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial
Saeed Erfanpoor, Seyed Reza Banihashemi, Ladan Mokhbaeralsafa, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial
Chunhua Zhou, Yuan-zheng Qiu, Jianxin Wang, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Promising Cytokine Adjuvants for Enhancing Tuberculosis Vaccine Immunity
Xuezhi Cao, Yang‐Xin Fu, Peng Hua
Vaccines (2024) Vol. 12, Iss. 5, pp. 477-477
Open Access | Times Cited: 3
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial
Ruizhi Zhang, Junshi Zhao, Xiaoping Zhu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
An overview of protein-based SARS-CoV-2 vaccines
Yogesh R. Suryawanshi
Vaccine (2023) Vol. 41, Iss. 42, pp. 6174-6193
Closed Access | Times Cited: 8
The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages
Qiaren He, Shiyu Sun, Xi Chen, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 146-146
Open Access | Times Cited: 11
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Alexandre E. Nowill, Manuel Caruso, Pedro O. de Campos‐Lima
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top